NGP talks to Robert Arendal, Chairman of the Cool Chain Association, about the issues faced by the pharmaceutical supply chain.
. As such, the 450-strong company manufactures some 50% of all veterinary medicines sold by Bayer.
Biopharmaceuticals have the potential to cure diseases rather than merely treat symptoms, and have fewer side effects because of their specificity.
Stakeholders point to the clinical costs as a barrier to innovation. The FDA has confirmed in its “Critical path report” that “Streamlining Clinical Trials” is one of the key priorities.
The number of counterfeit medicine packs seized by customs in Europe keeps on going up. This is a concern for both authorities and pharmaceutical companies who fear that counterfeit medications may end up in ordinary pharmacies.